Go Back to Match Results for "trials"
A Phase 1 Study Of Ramucirumab a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors Including CNS Tumors
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: solid tumors | Cancer | Solid Tumor
-
Age: Between 1 - 21 Years
-
Gender: Male or Female
Inclusion Criteria
Part A: participants with recurrent or refractory non-CNS solid tumors
Part B: participants with recurrent or refractory CNS tumors
Measurable or evaluable disease
No other therapeutic options
Performance Status: Karnofsky ?50% for participants >16 years and Lansky ?50 for participants ?16 years
Exclusion Criteria
Active or recent history of serious bleeding events
Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
Active or recent history of hypertensive crisis or hypertensive encephalopathy
Active non-healing wound or bone fracture
History of solid organ transplant
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
